Testing effectiveness (Phase 2)Study completedNCT02002312
What this trial is testing
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Who this might be right for
Metastatic Clear Cell Renal Cell Carcinoma
Radboud University Medical Center 14